Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ozored** is a marketed oral haematinic product range from Ozone Pharmaceuticals for iron and folate supplementation, including treatment or prevention of iron-deficiency anaemia and folate deficiency. The official Ozone Pharmaceuticals product page identifies an Ozored tablet containing ferrous ascorbate equivalent to elemental iron 100 mg, folic acid 1.5 mg, and zinc sulphate equivalent to elemental zinc 22.5 mg; it also lists an Ozored suspension containing ferrous ascorbate equivalent to elemental iron 30 mg and folic acid 550 mcg per 5 mL. Its therapeutic activity is nutritional replacement to support haemoglobin production, erythropoiesis, and normal folate-dependent cellular synthesis. ([ozonepharma.com](https://www.ozonepharma.com/nucleus/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ozored.